There are about 400 million patients of hepatitis in the world. Some of them are suffering from autoimmune hepatitis, a disease in which the body's immune system attacks liver cells.
A research team headed by Prof. TIAN Zhigang from the University of Science and Technology of China (USTC) recently discovered that a cytokine, a protein produced by white blood cells that act as chemical messengers between cells, could prevent mice liver from immune-mediated injury. The work, which was published at the recent issue of prestigious journal HEPATOLOGY, is applauded as providing guidance for the treatment of human autoimmune hepatitis.
Con-A-induced hepatitis is considered a good experimental model of human autoimmune hepatitis with characterized by leukocyte activation and infiltration of the liver. Using the model, Prof. Tian and colleagues found that injection of Interleukin-15 (IL-15), an important cytokine, could prevent mice from Con A-induced mortality, elevation of serum transaminase, liver necrosis, and hepatocyte apoptosis.
The researchers discovered that the mechanism for this lies in the fact that IL-15 pretreatment could decrease the NKT-derived IL-4, IL-5, and TNF- production, thereby resulting in less infiltration of eosinophils, which play a critical role in Con A-induced liver injury. Their studies indicate that IL-15 protects against Con A-induced liver injury via an NKT cell-dependent mechanism by reducing their production of IL-4, IL-5, and infiltration of eosinophils. These findings suggest that IL-15 may be of therapeutic relevance in human autoimmune-related hepatitis.
Tuesday, April 14, 2009
Monday, April 13, 2009
No Cancer! I got Vaccinated
FOR TWITTERS http://bit.ly/hnpzR
According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.
Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.
According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.
In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).
Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total '/>"/>
Source: PRWebCopyright©2009 Vocus, Inc.All rights reserved
According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.
Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.
According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.
In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).
Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total '/>"/>
Source: PRWebCopyright©2009 Vocus, Inc.All rights reserved
No Cancer! I avoided carcinogens and I got Vaccinated
OP ED-COMMENTARY
The following is the opinion of this writer only Alonzo Peters MD , and not TDB, or Brain Activity or Right Brain Activity.
If you can avoid cancer, would you, if it meant a dietary, and exercise-lifestyle change, including avoidance of unprotected sex (HPV/HIV) and alcoholic beverages? The researchers are betting no.
Or, would you continue to opt for no change in hopes that vaccines and other " new research " would come up with cures? It depends on whether you have cancer or not! It also depends on who the PAYOR IS ! Nevertheless there will be 16 billion predominantly on avoidance of cancer
in lieu of the possibility of exposure to a known cancer initiator- viral or otherwise.
The current British debate is whether new cures should be parceled out under a socialist system and who should get them to improve quantity and quality of life.
The greedy international reseachers and initial "investors" are quick to try to jack a price of the drug up in hopes that the US government will subsidize them with VA, Medicare and Medicaid funding. Mexico and other countries get UP TO 1/2 prices as negotiated. This is irregardless of whether the technology is based on sound science or not. If it does not mention the Kreb or Urea cycles, cytokines , HuR receptors ,inflammation you might as well forget it . It is a scam! The Human Genome Project as well as Stem Cell research is for naught until the Cytokine Cycle is introduced as priority and then tested in vitro
FOR TWITTERS http://bit.ly/hnpzR
According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.
Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.
According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.
In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).
Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total '/>"/>
Source: PRWebCopyright©2009 Vocus, Inc.All rights reserved
The following is the opinion of this writer only Alonzo Peters MD , and not TDB, or Brain Activity or Right Brain Activity.
If you can avoid cancer, would you, if it meant a dietary, and exercise-lifestyle change, including avoidance of unprotected sex (HPV/HIV) and alcoholic beverages? The researchers are betting no.
Or, would you continue to opt for no change in hopes that vaccines and other " new research " would come up with cures? It depends on whether you have cancer or not! It also depends on who the PAYOR IS ! Nevertheless there will be 16 billion predominantly on avoidance of cancer
in lieu of the possibility of exposure to a known cancer initiator- viral or otherwise.
The current British debate is whether new cures should be parceled out under a socialist system and who should get them to improve quantity and quality of life.
The greedy international reseachers and initial "investors" are quick to try to jack a price of the drug up in hopes that the US government will subsidize them with VA, Medicare and Medicaid funding. Mexico and other countries get UP TO 1/2 prices as negotiated. This is irregardless of whether the technology is based on sound science or not. If it does not mention the Kreb or Urea cycles, cytokines , HuR receptors ,inflammation you might as well forget it . It is a scam! The Human Genome Project as well as Stem Cell research is for naught until the Cytokine Cycle is introduced as priority and then tested in vitro
FOR TWITTERS http://bit.ly/hnpzR
According to CBDM.T®, the market and business intelligence company, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. The vaccine market could account for more than 25 billion by 2012.
Paris, France (PRWEB) April 13, 2009 -- Vaccines are substances used to stimulate the production of antibodies and provide immunity against one or several diseases. The vaccination was first used by Edward Jenner in 1796 against smallpox and furthered by Louis Pasteur in the 1870's. Vaccines are developed from whole dead or attenuated organisms, pathogen protein toxin (toxoids), pathogen surface molecules, inactivated or attenuated virus and more recently from DNA plasmid carrying an antigen-coding gene.
According to CBDM.T, vaccines represent one of the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human Papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the successful life cycle management of combination vaccines such as Pentacel and Infanrix, and expansion of the flu market. Childhood vaccines are the main segment, accounting for around 56% of the global vaccine market.
In 2008, 220 vaccines were under development from discovery (84 products), preclinical (39 products), clinical phase 1 (36 products), clinical phase 2 (50 products) to clinical phase 3 (with 14 products). 17 products were on the market. The leading top 5 pharmaceutical companies in this market are Sanofi-Aventis, GSK, Wyeth, Merck and Novartis (Chiron).
Vaccines are big business. According to CBDM.T®, the vaccine market is a huge and growing market valued at 16 billion in 2008 with an annual growth of about 15 to 18%. USA sales account for 45% of total '/>"/>
Source: PRWebCopyright©2009 Vocus, Inc.All rights reserved
Saturday, April 11, 2009
Tid bits. I mean TWIT BITS
Huntington's Chorea
Twit Bit-
http://bit.ly/qLlOj
Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons. Laboratory studies suggest that a single small interfering RNA could reduce production of the damaging Huntingtin protein in nearly half of people with the disease. Another 25 percent of patients might benefit from one of a set of four additional small interfering RNAs.
Phillip D. Zamore, an HHMI investigator at the University of Massachusetts Medical School in Worcester, and his colleagues reported their findings in an article published April 9, 2009, in the journal Current Biology.
There is no treatment for Huntington's disease, which is caused by a mutant form of the Huntingtin gene. Huntingtin is required for healthy nerve cells, but the mutant gene makes a toxic protein that contains excess amounts of the amino acid glutamine.
The key to whether the Huntingtin gene is normal or defective lies in a kind of genetic stutter: a repetitive sequence of the DNA triplet CAG, which codes for the amino acid glutamine. Stretches of CAG "repeats" appear in every human being's Huntingtin gene, but the length varies. Whereas the normal gene has a sequence of between six and 34 CAG repeats, the abnormal gene contains many more. In fact, any stretch of DNA containing more than 40 of these repeats ensures that its bearer will develop Huntington'sthe greater the number of repeats, the earlier the disease strikes and the greater its ferocity. The abnormal Huntingtin protein causes movement disorders, cognitive failure, and ultimately, death. Children who have a parent with Huntington's disease have a 50 percent chance of inheriting the disease themselves.
Zamore studies how RNA interference can be used to silence genes selectively. In the 1990s, he and other scientists
Contact: Jennifer Michalowski
mailto:Michalowskimichalow@hhmi.org
301-215-8576
Howard Hughes Medical InstituteSource:Eurekalert
On Globlastomas
Could Antineoplastins work the same way?
Twit BIT-
http://bit.ly/1IYCC
CHAPEL HILL Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.
The findings and potential treatment apply to a type of brain tumor called secondary glioblastoma multiforme (GBM). GBMs are part of a larger group of brain tumors called malignant gliomas, which is the type of cancer Senator Edward Kennedy suffers from.
A report of the research will appear in the April 10, 2009 issue of the journal Science. In experiments with tumor cells, the researchers reversed the effects of a mutation in a gene called isocitrate dehydrogenase-1 (IDH1) by replenishing a compound called α-ketoglutarate (α-KG).
"When the IDH1 gene is mutated, the level of α-KG is reduced, which in turn contributes to tumor growth by helping to increase the supply of nutrients and oxygen to tumor cells. When we added the α-KG to tumor cells, the effects caused by the IDH1 mutation were reversed," said Yue Xiong, Ph.D., William R. Kenan Jr., Distinguished Professor of Biochemistry and Biophysics and a member of the UNC Lineberger Comprehensive Cancer Center.
"If scientists can develop α-KG into a clinical drug, it could potentially be used for treating brain tumor patients who have this specific gene mutation. The α-KG compound is already there; it only needs to be modified to be used clinically, so that may save a lot of time," Xiong said.
Xiong is a corresponding author of the study along with Kun-Liang Guan, Ph.D., professor of pharmacology at the University of California, San Diego. The findings and potential treatment apply mostly to secondary GBM, rather than a different type of tumor called primary GBM. About 75 percent of secondary GBMs have mutations in the IDH1 gene, but only 5 percent of primary GBMs
Contact: Dianne Shawdgs@med.unc.edu919-966-7834University of North Carolina School of MedicineSource:Eurekalert
On Cloud computing of protein ressearh
Twit bit -
http://bit.ly/tOmf
Researchers at the Medical College of Wisconsin Biotechnology and Bioengineering Center in Milwaukee have just made the very expensive and promising area of protein research more accessible to scientists worldwide.
They have developed a set of free tools called ViPDAC (virtual proteomics data analysis cluster), to be used in combination with Amazon's inexpensive "cloud computing" service, which provides the option to rent processing time on its powerful servers; and free open-source software from the National Institutes of Health (NIH) and the University of Manitoba.
Their research appears online in Journal of Proteomic Research and is funded by the NIH Heart Lung and Blood Institute's Proteomics Innovation Center at the Medical College. Proteomics is a biomedical research term used to describe the large-scale study of all the proteins expressed by an organism. It usually involves the identification of proteins and determination of their modifications in both normal and disease states.
One of the major challenges for many laboratories setting up proteomics programs has been obtaining and maintaining the very costly computational infrastructure required for analysis of the vast flow of proteomics data generated by mass spectrometry instruments used to determine the elemental composition as well as chemical structure of a molecule, according to senior investigator, Simon Twigger, Ph.D., assistant professor of physiology.
"We're applying this technology in our Proteomics Center to study cardiovascular disease, the effects of radiation damage, and in our collaboration with the University of Wisconsin- Madison stem cell research group," he says.
With cloud computing making the analysis less expensive and more accessible, many more users can set up and customize their own systems. Investigators can analyze their data in greater depth than previously possible, making it possible for them to learn more about t'/>"/>
Contact: Eileen La Susalasusa@mcw.edu414-456-4700Medical College of WisconsinSource:Eurekalert
ON Protein Increase in PLANTS for FOOD
For my Twitters - http://bit.ly/KTcME
RIVERSIDE, Calif. The small flowering plant Arabidopsis is widely used in laboratories as a model organism in plant biology.
A member of the mustard family, Arabidopsis offers researchers several advantages such as a completely sequenced genome, a compact size, a life-cycle of about only six weeks from seed to seed, easy cultivation and high seed production.
Now Daniel Gallie, a professor of biochemistry at UC Riverside, has received a three-year grant of nearly $1.75 million from the National Science Foundation to study how each Arabidopsis gene is converted into protein and how plants control this process.
The research can help improve protein production in crops. Protein-rich crops improve the diet of humans directly and promote livestock productivity for a growing world population. Besides their nutritional advantages, these crops also reduce the environmental impact of livestock production by potentially reducing the acreage required for agriculture.
"Understanding how most genes, out of the more than 25,000 genes in Arabidopsis, are converted into protein will be important in understanding how plants control protein synthesis," Gallie said. "This knowledge is essential in improving protein production in crops."
With the advent of the complete sequence of the genome of Arabidopsis and other plant species, researchers are now in a position of being able to understand how every gene in an organism is converted into protein.
"This, in conjunction with the development of other recent technologies, such as the ability to identify mutants in most genes as well as to analyze virtually all genes in Arabidopsis on a chip no larger than a fingertip, makes such a study possible for the first time," Gallie said.
He explained that the process of protein producti'/>"/>
Contact: Iqbal Pittalwalaiqbal@ucr.edu951-827-6050University of California - RiversideSource:Eurekalert
On Information transfer
URL- http://www.youtube.com/watch?v=VQ3d3KigPQM
Bit - http://bit.ly/1AbtCW
On Dancing
URL - http://www.youtube.com/watch?v=cL9Wu2kWwSY
Bit- http://bit.ly/MbliY
I love you! I love you in Jesus name and there is nothing that you can do about it!
Twit Bit-
http://bit.ly/qLlOj
Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons. Laboratory studies suggest that a single small interfering RNA could reduce production of the damaging Huntingtin protein in nearly half of people with the disease. Another 25 percent of patients might benefit from one of a set of four additional small interfering RNAs.
Phillip D. Zamore, an HHMI investigator at the University of Massachusetts Medical School in Worcester, and his colleagues reported their findings in an article published April 9, 2009, in the journal Current Biology.
There is no treatment for Huntington's disease, which is caused by a mutant form of the Huntingtin gene. Huntingtin is required for healthy nerve cells, but the mutant gene makes a toxic protein that contains excess amounts of the amino acid glutamine.
The key to whether the Huntingtin gene is normal or defective lies in a kind of genetic stutter: a repetitive sequence of the DNA triplet CAG, which codes for the amino acid glutamine. Stretches of CAG "repeats" appear in every human being's Huntingtin gene, but the length varies. Whereas the normal gene has a sequence of between six and 34 CAG repeats, the abnormal gene contains many more. In fact, any stretch of DNA containing more than 40 of these repeats ensures that its bearer will develop Huntington'sthe greater the number of repeats, the earlier the disease strikes and the greater its ferocity. The abnormal Huntingtin protein causes movement disorders, cognitive failure, and ultimately, death. Children who have a parent with Huntington's disease have a 50 percent chance of inheriting the disease themselves.
Zamore studies how RNA interference can be used to silence genes selectively. In the 1990s, he and other scientists
Contact: Jennifer Michalowski
mailto:Michalowskimichalow@hhmi.org
301-215-8576
Howard Hughes Medical InstituteSource:Eurekalert
On Globlastomas
Could Antineoplastins work the same way?
Twit BIT-
http://bit.ly/1IYCC
CHAPEL HILL Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.
The findings and potential treatment apply to a type of brain tumor called secondary glioblastoma multiforme (GBM). GBMs are part of a larger group of brain tumors called malignant gliomas, which is the type of cancer Senator Edward Kennedy suffers from.
A report of the research will appear in the April 10, 2009 issue of the journal Science. In experiments with tumor cells, the researchers reversed the effects of a mutation in a gene called isocitrate dehydrogenase-1 (IDH1) by replenishing a compound called α-ketoglutarate (α-KG).
"When the IDH1 gene is mutated, the level of α-KG is reduced, which in turn contributes to tumor growth by helping to increase the supply of nutrients and oxygen to tumor cells. When we added the α-KG to tumor cells, the effects caused by the IDH1 mutation were reversed," said Yue Xiong, Ph.D., William R. Kenan Jr., Distinguished Professor of Biochemistry and Biophysics and a member of the UNC Lineberger Comprehensive Cancer Center.
"If scientists can develop α-KG into a clinical drug, it could potentially be used for treating brain tumor patients who have this specific gene mutation. The α-KG compound is already there; it only needs to be modified to be used clinically, so that may save a lot of time," Xiong said.
Xiong is a corresponding author of the study along with Kun-Liang Guan, Ph.D., professor of pharmacology at the University of California, San Diego. The findings and potential treatment apply mostly to secondary GBM, rather than a different type of tumor called primary GBM. About 75 percent of secondary GBMs have mutations in the IDH1 gene, but only 5 percent of primary GBMs
Contact: Dianne Shawdgs@med.unc.edu919-966-7834University of North Carolina School of MedicineSource:Eurekalert
On Cloud computing of protein ressearh
Twit bit -
http://bit.ly/tOmf
Researchers at the Medical College of Wisconsin Biotechnology and Bioengineering Center in Milwaukee have just made the very expensive and promising area of protein research more accessible to scientists worldwide.
They have developed a set of free tools called ViPDAC (virtual proteomics data analysis cluster), to be used in combination with Amazon's inexpensive "cloud computing" service, which provides the option to rent processing time on its powerful servers; and free open-source software from the National Institutes of Health (NIH) and the University of Manitoba.
Their research appears online in Journal of Proteomic Research and is funded by the NIH Heart Lung and Blood Institute's Proteomics Innovation Center at the Medical College. Proteomics is a biomedical research term used to describe the large-scale study of all the proteins expressed by an organism. It usually involves the identification of proteins and determination of their modifications in both normal and disease states.
One of the major challenges for many laboratories setting up proteomics programs has been obtaining and maintaining the very costly computational infrastructure required for analysis of the vast flow of proteomics data generated by mass spectrometry instruments used to determine the elemental composition as well as chemical structure of a molecule, according to senior investigator, Simon Twigger, Ph.D., assistant professor of physiology.
"We're applying this technology in our Proteomics Center to study cardiovascular disease, the effects of radiation damage, and in our collaboration with the University of Wisconsin- Madison stem cell research group," he says.
With cloud computing making the analysis less expensive and more accessible, many more users can set up and customize their own systems. Investigators can analyze their data in greater depth than previously possible, making it possible for them to learn more about t'/>"/>
Contact: Eileen La Susalasusa@mcw.edu414-456-4700Medical College of WisconsinSource:Eurekalert
ON Protein Increase in PLANTS for FOOD
For my Twitters - http://bit.ly/KTcME
RIVERSIDE, Calif. The small flowering plant Arabidopsis is widely used in laboratories as a model organism in plant biology.
A member of the mustard family, Arabidopsis offers researchers several advantages such as a completely sequenced genome, a compact size, a life-cycle of about only six weeks from seed to seed, easy cultivation and high seed production.
Now Daniel Gallie, a professor of biochemistry at UC Riverside, has received a three-year grant of nearly $1.75 million from the National Science Foundation to study how each Arabidopsis gene is converted into protein and how plants control this process.
The research can help improve protein production in crops. Protein-rich crops improve the diet of humans directly and promote livestock productivity for a growing world population. Besides their nutritional advantages, these crops also reduce the environmental impact of livestock production by potentially reducing the acreage required for agriculture.
"Understanding how most genes, out of the more than 25,000 genes in Arabidopsis, are converted into protein will be important in understanding how plants control protein synthesis," Gallie said. "This knowledge is essential in improving protein production in crops."
With the advent of the complete sequence of the genome of Arabidopsis and other plant species, researchers are now in a position of being able to understand how every gene in an organism is converted into protein.
"This, in conjunction with the development of other recent technologies, such as the ability to identify mutants in most genes as well as to analyze virtually all genes in Arabidopsis on a chip no larger than a fingertip, makes such a study possible for the first time," Gallie said.
He explained that the process of protein producti'/>"/>
Contact: Iqbal Pittalwalaiqbal@ucr.edu951-827-6050University of California - RiversideSource:Eurekalert
On Information transfer
URL- http://www.youtube.com/watch?v=VQ3d3KigPQM
Bit - http://bit.ly/1AbtCW
On Dancing
URL - http://www.youtube.com/watch?v=cL9Wu2kWwSY
Bit- http://bit.ly/MbliY
I love you! I love you in Jesus name and there is nothing that you can do about it!
Tuesday, April 7, 2009
4-7-9 PM
http://bit.ly/oMBf -for Twitterites
HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in preparation for FDA submission. Both tests were recently awarded FDA premarket approval. According to Hologic, their Cervista HPV HR clinical trial involved over 4,000 women spread across 89 sites throughout the United States and constituted one of the largest and most demographically diverse clinical trials ever conducted in the United States.
SeqWright was selected to perform the sequencing-based validations of Hologic's HPV Diagnostics assays after successfully completing several of Hologic's previous clinical trials, which all led to FDA approvals. SeqWright maintains advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.
Sequencing for Hologic's clinical trials was performed under GLP guidelines (4X-bidirectional sequencing, stringent controls, full documentation) and all samples were continuously tracked and monitored. The bioinformatics provided by SeqWright were also vital to trial success and were used to implement Hologic's HPV genotyping analysis as well as to create a customized clinical trial decision tree algorithm. These services led to a streamlined, reliable and efficient testing regimen in support of Hologic's two recently approved HPV Diagnostics.
SeqWright CEO, Dr. Fei Lu, M.D. stated, "We wish to congratulate Hologic on the '/>"/> pre-market approvals of their new HPV diagnostic tests and we are proud of the work we performed in support of their efforts."
About SeqWright:
SeqWright Incorporated is a world-class genomic services support organization based in Houston, TX with more than fifteen years of experience specializing in state of the art Molecular Biology and Genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright and its services, please visit www.seqwright.com.
SOURCE SeqWright Inc.Copyright©2009 PR Newswire.All rights reserved
HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in preparation for FDA submission. Both tests were recently awarded FDA premarket approval. According to Hologic, their Cervista HPV HR clinical trial involved over 4,000 women spread across 89 sites throughout the United States and constituted one of the largest and most demographically diverse clinical trials ever conducted in the United States.
SeqWright was selected to perform the sequencing-based validations of Hologic's HPV Diagnostics assays after successfully completing several of Hologic's previous clinical trials, which all led to FDA approvals. SeqWright maintains advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.
Sequencing for Hologic's clinical trials was performed under GLP guidelines (4X-bidirectional sequencing, stringent controls, full documentation) and all samples were continuously tracked and monitored. The bioinformatics provided by SeqWright were also vital to trial success and were used to implement Hologic's HPV genotyping analysis as well as to create a customized clinical trial decision tree algorithm. These services led to a streamlined, reliable and efficient testing regimen in support of Hologic's two recently approved HPV Diagnostics.
SeqWright CEO, Dr. Fei Lu, M.D. stated, "We wish to congratulate Hologic on the '/>"/> pre-market approvals of their new HPV diagnostic tests and we are proud of the work we performed in support of their efforts."
About SeqWright:
SeqWright Incorporated is a world-class genomic services support organization based in Houston, TX with more than fifteen years of experience specializing in state of the art Molecular Biology and Genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright and its services, please visit www.seqwright.com.
SOURCE SeqWright Inc.Copyright©2009 PR Newswire.All rights reserved
4-7-9 Updates
http://bit.ly/puPdu Sprint commercial but good perspective on twitter and integration
visualization example: http://tinyurl.com/d8yr3t it mentions twitter too (via @canuckflack)
http://blog.searchenginewatch.com/090407-140506 - page view increase with spokesperson
http://bit.ly/UFDx3
http://www.itbusinessedge.com/cm/blogs/weinschenk/the-status-of-electronic-health-care-upgraded-to-probable/?cs=31655
medical electronic care
10 signs of needing a life http://www.minervity.com/?p=2392
RT franchiselookup . The name speaks growth
Opportunity for SL http://www.bio-medicine.org/biology-technology-1/Ansell-Healthcare-Espresses-Firm-Commitment-to-Support-Continued-Education-of-Healthcare-Professionals-Worldwide-11417-1/
http://bit.ly/iehnq
BRUSSELS, April 7 /PRNewswire/ --
- European Operating Room Nurses Association (EORNA) to Confirm AnsellCares(R), the Ansell Global Healthcare Educational Program, Accepted for Accreditation
Earlier today, Ansell Healthcare, the global leader in healthcare barrier protective solutions, has announced it has taken a further step in supporting the global healthcare professionals community in the area of continued education.
After receiving earlier confirmation of acceptance by its US counterpart (AORN), the AnsellCares(R) educational courses have now also received confirmation of acceptance by the European Operating Room Nurses Association. Focusing on infection control, allergy prevention, barrier protection and nursing procedures, the AnsellCares(R) courses perfectly link into the requirements of continued education for healthcare workers around the world. The Ansell educational courses are actually the first courses offered under the newly launched EORNA Accreditation Council for Education (ACE), and will be made accessible via a web-based portal under the EORNA Academy header.
The AnsellCares(R) self-study courses will initially be made available via the EORNA website. EORNA members will be offered logging in to EORNA Academy section of the website, and make their choice on the "offering" page. AnsellCares course content can then be accessed and downloaded. Tests will taken online, delivering final results and accreditation points through a EORNA ACE certificate.
"We are pleased to further extend our support to healthcare workers in Europe, by offering web-based educational courses," says Irini Antoniadou, President of EORNA. "At EORNA, we wholeheartedly back the high quality and thoroughness of AnsellCares courses. They effectively package best practice for nursing professionals," she continues.
AnsellCares(R) educational programmes have been approv
See RNA? http://www.bio-medicine.org/biology-technology-1/Researchers-develop-new-way-to-see-single-RNA-molecules-inside-living-cells-11415-1/
Biomedical engineers have developed a new type of probe that allows them to visualize single ribonucleic acid (RNA) molecules within live cells more easily than existing methods. The tool will help scientists learn more about how RNA operates within living cells.
Techniques scientists currently use to image these transporters of genetic information within cells have several drawbacks, including the need for synthetic RNA or a large number of fluorescent molecules. The fluorescent probes developed at the Georgia Institute of Technology circumvent these issues.
"The probes we designed shine bright, are small and easy to assemble, bind rapidly to their targets, and can be imaged for hours. These characteristics make them a great choice for studying the movement and location of RNA inside a single cell and the interaction between RNA and binding proteins," said Philip Santangelo, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
Details of the probe production process and RNA imaging strategy were published online in the journal Nature Methods on April 6. In addition to Santangelo, Georgia Tech graduate student Aaron Lifland, Emory University associate professor Gary Bassell and Vanderbilt University professor James Crowe Jr. also contributed to this research. This research was funded by new faculty support from Georgia Tech.
In the study, the probes produced by attaching a few small fluorescent molecules called fluorophores to a modified nucleic acid sequence and combining the sequences with a protein exhibited single-molecule sensitivity and allowed the researchers to target and follow native RNA and non-engineered viral RNA in living cells.
"The great thing about these probes is that they recognize RNA sequences and bind to them using the same base pairing most people are familiar with in regards to DNA," explained Santangelo. "By addin'/>"/>
Contact: Abby Vogelavogel@gatech.edu404-385-3364Georgia Institute of Technology Research NewsSource:Eurekalert
http://www.themarketguardian.com/2009/04/congressional-watchdog-to-drop-a-bombshell-on-the-us-financial-industry/
http://bit.ly/idPt0
RT MarketGuardianCongressional Watchdog to Drop a Bombshell on the US Financial Industry: “set to call for shareholders in.. http://tinyurl.com/cr7ns8
http://bit.ly/iehnq
pete4docSqueeze on US med Doctors has to involve updates on CME also with e-med and dim reimbursements Here is how nurses do it http://bit.ly/iehnq less than 5 seconds ago
pete4dochttp://bit.ly/tjm7 For all the biologics that are going anywhere and whyless than 5 seconds ago from web
visualization example: http://tinyurl.com/d8yr3t it mentions twitter too (via @canuckflack)
http://blog.searchenginewatch.com/090407-140506 - page view increase with spokesperson
http://bit.ly/UFDx3
http://www.itbusinessedge.com/cm/blogs/weinschenk/the-status-of-electronic-health-care-upgraded-to-probable/?cs=31655
medical electronic care
10 signs of needing a life http://www.minervity.com/?p=2392
RT franchiselookup . The name speaks growth
Opportunity for SL http://www.bio-medicine.org/biology-technology-1/Ansell-Healthcare-Espresses-Firm-Commitment-to-Support-Continued-Education-of-Healthcare-Professionals-Worldwide-11417-1/
http://bit.ly/iehnq
BRUSSELS, April 7 /PRNewswire/ --
- European Operating Room Nurses Association (EORNA) to Confirm AnsellCares(R), the Ansell Global Healthcare Educational Program, Accepted for Accreditation
Earlier today, Ansell Healthcare, the global leader in healthcare barrier protective solutions, has announced it has taken a further step in supporting the global healthcare professionals community in the area of continued education.
After receiving earlier confirmation of acceptance by its US counterpart (AORN), the AnsellCares(R) educational courses have now also received confirmation of acceptance by the European Operating Room Nurses Association. Focusing on infection control, allergy prevention, barrier protection and nursing procedures, the AnsellCares(R) courses perfectly link into the requirements of continued education for healthcare workers around the world. The Ansell educational courses are actually the first courses offered under the newly launched EORNA Accreditation Council for Education (ACE), and will be made accessible via a web-based portal under the EORNA Academy header.
The AnsellCares(R) self-study courses will initially be made available via the EORNA website. EORNA members will be offered logging in to EORNA Academy section of the website, and make their choice on the "offering" page. AnsellCares course content can then be accessed and downloaded. Tests will taken online, delivering final results and accreditation points through a EORNA ACE certificate.
"We are pleased to further extend our support to healthcare workers in Europe, by offering web-based educational courses," says Irini Antoniadou, President of EORNA. "At EORNA, we wholeheartedly back the high quality and thoroughness of AnsellCares courses. They effectively package best practice for nursing professionals," she continues.
AnsellCares(R) educational programmes have been approv
See RNA? http://www.bio-medicine.org/biology-technology-1/Researchers-develop-new-way-to-see-single-RNA-molecules-inside-living-cells-11415-1/
Biomedical engineers have developed a new type of probe that allows them to visualize single ribonucleic acid (RNA) molecules within live cells more easily than existing methods. The tool will help scientists learn more about how RNA operates within living cells.
Techniques scientists currently use to image these transporters of genetic information within cells have several drawbacks, including the need for synthetic RNA or a large number of fluorescent molecules. The fluorescent probes developed at the Georgia Institute of Technology circumvent these issues.
"The probes we designed shine bright, are small and easy to assemble, bind rapidly to their targets, and can be imaged for hours. These characteristics make them a great choice for studying the movement and location of RNA inside a single cell and the interaction between RNA and binding proteins," said Philip Santangelo, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
Details of the probe production process and RNA imaging strategy were published online in the journal Nature Methods on April 6. In addition to Santangelo, Georgia Tech graduate student Aaron Lifland, Emory University associate professor Gary Bassell and Vanderbilt University professor James Crowe Jr. also contributed to this research. This research was funded by new faculty support from Georgia Tech.
In the study, the probes produced by attaching a few small fluorescent molecules called fluorophores to a modified nucleic acid sequence and combining the sequences with a protein exhibited single-molecule sensitivity and allowed the researchers to target and follow native RNA and non-engineered viral RNA in living cells.
"The great thing about these probes is that they recognize RNA sequences and bind to them using the same base pairing most people are familiar with in regards to DNA," explained Santangelo. "By addin'/>"/>
Contact: Abby Vogelavogel@gatech.edu404-385-3364Georgia Institute of Technology Research NewsSource:Eurekalert
http://www.themarketguardian.com/2009/04/congressional-watchdog-to-drop-a-bombshell-on-the-us-financial-industry/
http://bit.ly/idPt0
RT MarketGuardianCongressional Watchdog to Drop a Bombshell on the US Financial Industry: “set to call for shareholders in.. http://tinyurl.com/cr7ns8
http://bit.ly/iehnq
pete4docSqueeze on US med Doctors has to involve updates on CME also with e-med and dim reimbursements Here is how nurses do it http://bit.ly/iehnq less than 5 seconds ago
pete4dochttp://bit.ly/tjm7 For all the biologics that are going anywhere and whyless than 5 seconds ago from web
Subscribe to:
Posts (Atom)